SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are actively debating the impact of volatile geopolitical headlines and contradictory leadership commentary on the escalating conflict in the Middle East, with many traders questioning the reliability of ongoing negotiations and their potential to stabilize energy markets. The conversation is dominated by skepticism regarding policy effectiveness and widespread uncertainty, leading investors to hedge positions while monitoring key technical levels for potential volatility shifts.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is trending as market participants weigh heightened geopolitical tensions in the Middle East against a potential relief rally fueled by rumors of diplomatic negotiations in Pakistan. Community sentiment is deeply divided, with traders closely monitoring the Strait of Hormuz, potential shifts in oil supply, and the impact of technical oversold conditions on institutional positioning.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy Co. is experiencing extreme volatility and intense community interest driven by its recent NASDAQ debut and speculative excitement surrounding potential oil drilling rights in Greenland. Investors are actively debating the company's long-term potential as a major energy player versus concerns about it being a high-risk, thin-float momentum play prone to rapid price swings.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Magnificent Seven ETF ($MAGS) is a major focus for investors navigating market volatility, as community members debate whether these tech leaders will continue to drive market gains or suffer from an AI bubble, stretched valuations, and shifting macro conditions. Active discussions are heavily split between those viewing the basket as a long-term 'buy-and-hold' play and others warning that broader market rotation and expensive AI capital expenditures suggest a correction is imminent.

TLGY Acquisition Corp. is a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Jin-Goon Kim in May 2021 and is headquartered in Wilmington, DE.

TLGY Acquisition Corp - Ordinary Shares - Class A

TLGY is generating significant market interest as investors monitor its vertical alignment and strategic business combination to form StablecoinX. Community discussion remains heavily focused on the pivotal role of shared leadership across related entities and the potential impact of these developments on the emerging digital asset and stablecoin treasury landscape.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently garnering significant community attention driven by broader debates over its role in the crypto market cycle and ongoing development of various memecoin projects within its ecosystem. While some investors remain cautious about volatility, others are actively tracking accumulation patterns and long-term utility plays as market participants assess the asset's potential for future growth.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting strong Week 40 Phase 3 data, which demonstrates sustained efficacy and positions the company as a potential best-in-class contender in the HS treatment market. The community is actively discussing the potential for a near-term buyout as analyst sentiment shifts, though many investors remain wary of the stock's persistent volatility and institutional market-making patterns.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is generating buzz as community members highlight its role in the "Agentic Economy," emphasizing the protocol's chain abstraction and recent integrations that enable AI agents to transact autonomously. While some investors express frustration over price action and sentiment, the discourse is heavily focused on long-term utility, with many tracking developments like NEAR Intents and the potential for increased institutional adoption.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is currently a focal point for investors speculating on energy sector tailwinds as escalating Middle East tensions and potential supply disruptions keep crude oil prices elevated. The community remains deeply divided, with bulls betting on a short squeeze and long-term oil price strength while skeptics highlight concerns regarding the company's fundamentals, recent insider selling, and potential dilution risks.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as traders speculate on a potential short squeeze, fueled by bullish sentiment in Bitcoin and increasing investor focus on the long-term potential of the company's Helios data center infrastructure. The community is actively debating the company's pivot toward AI-related power demand, while discussions regarding the upcoming delisting from the Canadian exchange and the lack of proactive management updates remain prominent points of contention.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?

Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 16, 2026 Insiders may stand to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS...

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 7% in the pre-market session.Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share (ADS) or ordinary share they own. Meanwhile, each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for every common or preferred share they own. The combined company will advance a fresh portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-biotherapeutics-combine-clywedog-therapeutics-target">said</a>. Four clinical data milestones are expected within 18 months of transaction closing, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BRNS">BRNS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.The combined company will be renamed “Clywedog Therapeutics, Inc.” and is expected to trade on the Nasdaq under the new ticker symbol “CLYD.” Barinthus Bio ADSs will no longer trade on the Nasdaq following the closing of the transaction in the first half of 2026.The combined company will initially focus on advancing its pipeline in Type 1 diabetes, Type 2 diabetes, and celiac disease, Barinthus said. It is expected to have a cash runway into 2027 with additional investments from Clywedog’s existing investors, OrbiMed and Torrey Pines Investment LLC.Upon closing, shareholders of Barinthus Bio are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis.BRNS shares are up by 22% this year and 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.

Equity

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.


Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Barinthus Biotherapeutics Plc. - ADR

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.28	--	--	N/A
Q4 '25	-$0.34	-$0.27	21.74%	BEAT
Q3 '25	-$0.40	-$0.36	8.86%	BEAT
Q2 '25	-$0.33	-$0.52	-57.58%	MISSED
Q1 '25	-$0.36	-$0.49	-36.11%	MISSED

BRNS
Barinthus Biotherapeutics PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest BRNS News

BRNSBarinthus Biotherapeutics PLC - ADR